Stay updated on Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel

Sign up to get notified when there's something new on the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov website revision updated from v3.8.0 to v3.8.1, with no change to the clinical study record.
    Difference
    0.0%
    Check dated 2026-11-18T11:06:33.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The record presents details of Pfizer’s completed Phase 3 comparison of PF-05280014 and EU-sourced trastuzumab, both combined with paclitaxel, for HER2-positive metastatic breast cancer. It also includes study locations, outcome measures, publications, and information about requesting de-identified participant data.
    Difference
    100%
    Check dated 2026-11-11T12:20:09.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The study record remains on a 403 Forbidden error page, with no visible changes to the page.
    Difference
    0.2%
    Check dated 2026-10-28T13:56:18.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    A notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page, and the site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T13:43:49.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T13:27:38.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error with a minimal header and a Home link, replacing the previously available study details and related navigation.
    Difference
    17%
    Check dated 2026-09-23T19:51:02.000Z thumbnail image

Stay in the know with updates to Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel

Enter your email address, and we'll notify you when there's something new on the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page.